{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:38:23Z","timestamp":1787841503540,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Japan Breast Cancer Research Group"},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12282-026-01876-x","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:52:13Z","timestamp":1781081533000},"page":"1036-1046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality-of-life assessment in the randomized JBCRG-M06\/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7162-1515","authenticated-orcid":false,"given":"Tsuguo","family":"Iwatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-0278","authenticated-orcid":false,"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6732-8030","authenticated-orcid":false,"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7961-9417","authenticated-orcid":false,"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9991-0228","authenticated-orcid":false,"given":"Yasuyuki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-9655","authenticated-orcid":false,"given":"Hideo","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-1739","authenticated-orcid":false,"given":"Yasuaki","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1640-5315","authenticated-orcid":false,"given":"Eriko","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3202-5512","authenticated-orcid":false,"given":"Tadahiko","family":"Shien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1986-6643","authenticated-orcid":false,"given":"Uhi","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Osaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4344-3317","authenticated-orcid":false,"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6479-1660","authenticated-orcid":false,"given":"Toshinari","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"1876_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_351222","volume":"42","author":"M Gion","year":"2022","unstructured":"Gion M, Trapani D, Cort\u00e9s A, Valenza C, Lin N, Cort\u00e9s J, et al. Systemic therapy for HER2-positive metastatic breast cancer: moving into a new era. Am Soc Clin Oncol Educ Book. 2022;42:1\u201311. https:\/\/doi.org\/10.1200\/EDBK_351222.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1876_CR2","first-page":"40","volume":"19","author":"P Exman","year":"2021","unstructured":"Exman P, Tolaney SM. HER2-positive metastatic breast cancer: a comprehensive review. Clin Adv Hematol Oncol. 2021;19:40\u201350.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1876_CR3","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/jjco\/hyac054","volume":"52","author":"M Sawaki","year":"2022","unstructured":"Sawaki M, Shimomura A, Shien T, Iwata H. Management of breast cancer in older patients. Jpn J Clin Oncol. 2022;52:682\u20139. https:\/\/doi.org\/10.1093\/jjco\/hyac054.","journal-title":"Jpn J Clin Oncol"},{"key":"1876_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00432-023-05530-3","volume":"150","author":"J Wang","year":"2024","unstructured":"Wang J, Yu Y, Lin Q, Zhang J, Song C. Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2024;150:21. https:\/\/doi.org\/10.1007\/s00432-023-05530-3.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1876_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12282-024-01545-x","volume":"31","author":"T Iwamoto","year":"2024","unstructured":"Iwamoto T, Kumamaru H, Niikura N, Sagara Y, Miyashita M, Konishi T, et al. Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry. Breast Cancer. 2024;31:185\u201394. https:\/\/doi.org\/10.1007\/s12282-024-01545-x.","journal-title":"Breast Cancer"},{"key":"1876_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1113216.","journal-title":"N Engl J Med"},{"key":"1876_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1413513.","journal-title":"N Engl J Med"},{"key":"1876_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:519\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(19)30863-0.","journal-title":"Lancet Oncol"},{"key":"1876_CR9","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol"},{"key":"1876_CR10","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.22.00519","volume":"40","author":"SH Giordano","year":"2022","unstructured":"Giordano SH, Franzoi MAB, Temin S, Anders CK, Chandarlapaty S, Crews JR, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:2612\u201335. https:\/\/doi.org\/10.1200\/JCO.22.00519.","journal-title":"J Clin Oncol"},{"key":"1876_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12282-023-01505-x","volume":"30","author":"M Terada","year":"2023","unstructured":"Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, et al. The Japanese Breast Cancer Society clinical practice guidelines for systemic treatment of breast cancer, 2022 edition. Breast Cancer. 2023;30:872\u201384. https:\/\/doi.org\/10.1007\/s12282-023-01505-x.","journal-title":"Breast Cancer"},{"key":"1876_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.954179","volume":"12","author":"X Chen","year":"2022","unstructured":"Chen X, Wu C, Bai D, Gao J, Hou C, Chen T, et al. Health-related quality of life in breast cancer patients in Asia: a meta-analysis and systematic review. Front Oncol. 2022;12:954179. https:\/\/doi.org\/10.3389\/fonc.2022.954179.","journal-title":"Front Oncol"},{"key":"1876_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251337493","volume":"17","author":"BF Vaca-Cartagena","year":"2025","unstructured":"Vaca-Cartagena BF, Mesa-Chavez F, Guajardo ASF, Azim HA Jr, Rotolo F, Platas A, et al. Evaluating changes in the breast cancer-related quality of life of young women with breast cancer: long-term results from a multicenter prospective cohort. Ther Adv Med Oncol. 2025;17:17588359251337493. https:\/\/doi.org\/10.1177\/17588359251337493.","journal-title":"Ther Adv Med Oncol"},{"key":"1876_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01603-w","volume":"18","author":"M Verrill","year":"2020","unstructured":"Verrill M, Wardley AM, Retzler J, Smith AB, Bottomley C, N\u00ed Dhochartaigh S, et al. Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage. Health Qual Life Outcomes. 2020;18:353. https:\/\/doi.org\/10.1186\/s12955-020-01603-w.","journal-title":"Health Qual Life Outcomes"},{"key":"1876_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ogc.2021.11.008","volume":"49","author":"HW Hazard-Jenkins","year":"2022","unstructured":"Hazard-Jenkins HW. Breast cancer survivorship-mitigating treatment effects on quality of life and improving survival. Obstet Gynecol Clin North Am. 2022;49:209\u201318. https:\/\/doi.org\/10.1016\/j.ogc.2021.11.008.","journal-title":"Obstet Gynecol Clin North Am"},{"key":"1876_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.suc.2022.08.014","volume":"103","author":"J Abdo","year":"2023","unstructured":"Abdo J, Ortman H, Rodriguez N, Tillman R, Riordan EO, Seydel A. Quality of life issues following breast cancer treatment. Surg Clin North Am. 2023;103:155\u201367. https:\/\/doi.org\/10.1016\/j.suc.2022.08.014.","journal-title":"Surg Clin North Am"},{"key":"1876_CR17","doi-asserted-by":"publisher","first-page":"104603","DOI":"10.1016\/j.breast.2025.104603","volume":"84","author":"K Gelmon","year":"2025","unstructured":"Gelmon K, Villarreal-Garza C, Aubel D, Rugo HS, Mau\u00e9s J, Travado L, et al. Improving the quality of life of people with advanced breast cancer: a global expert review and call-to-action. Breast. 2025;84:104603. https:\/\/doi.org\/10.1016\/j.breast.2025.104603.","journal-title":"Breast"},{"key":"1876_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3892\/ol.2025.15254","volume":"30","author":"M Godiveau","year":"2025","unstructured":"Godiveau M, Jahanmohan JP, Abrial C, Durando X. Chemotherapy-induced peripheral neuropathy in patients with breast cancer treated with taxanes (review). Oncol Lett. 2025;30:508. https:\/\/doi.org\/10.3892\/ol.2025.15254.","journal-title":"Oncol Lett"},{"key":"1876_CR19","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1007\/s10072-021-05576-6","volume":"42","author":"T Li","year":"2021","unstructured":"Li T, Mizrahi D, Goldstein D, Kiernan MC, Park SB. Chemotherapy and peripheral neuropathy. Neurol Sci. 2021;42:4109\u201321. https:\/\/doi.org\/10.1007\/s10072-021-05576-6.","journal-title":"Neurol Sci"},{"key":"1876_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(16)31891-8.","journal-title":"Lancet"},{"key":"1876_CR21","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1093\/annonc\/mdt274","volume":"24","author":"J Cort\u00e9s","year":"2013","unstructured":"Cort\u00e9s J, Baselga J, Im YH, Im SA, Pivot X, Ross G, et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol. 2013;24:2630\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdt274.","journal-title":"Ann Oncol"},{"key":"1876_CR22","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO-24-01888","volume":"43","author":"T Yamashita","year":"2025","unstructured":"Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, et al. Trastuzumab-pertuzumab plus eribulin or taxane as first-line chemotherapy for human epidermal growth factor 2-positive locally advanced\/metastatic breast cancer: the randomized noninferiority phase III EMERALD trial. J Clin Oncol. 2025;43:1302\u201313. https:\/\/doi.org\/10.1200\/JCO-24-01888.","journal-title":"J Clin Oncol"},{"key":"1876_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s13063-020-04341-y","volume":"21","author":"T Yamashita","year":"2020","unstructured":"Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, et al. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06\/EMERALD). Trials. 2020;21:391. https:\/\/doi.org\/10.1186\/s13063-020-04341-y.","journal-title":"Trials"},{"key":"1876_CR24","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2013.879","volume":"309","author":"M Calvert","year":"2013","unstructured":"Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309:814\u201322. https:\/\/doi.org\/10.1001\/jama.2013.879.","journal-title":"JAMA"},{"key":"1876_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081123","volume":"389","author":"S Hopewell","year":"2025","unstructured":"Hopewell S, Chan AW, Collins GS, Hr\u00f3bjartsson A, Moher D, Schulz KF, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123. https:\/\/doi.org\/10.1136\/bmj-2024-081123.","journal-title":"BMJ"},{"key":"1876_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"key":"1876_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s41669-024-00478-7","volume":"8","author":"SM Khoirunnisa","year":"2024","unstructured":"Khoirunnisa SM, Suryanegara FDA, de Jong LA, Setiawan D, Postma MJ. A systematic review of health-related quality of life in women with HER2-positive metastatic breast cancer treated with trastuzumab. PharmacoEconomics - Open. 2024;8:511\u201324. https:\/\/doi.org\/10.1007\/s41669-024-00478-7.","journal-title":"PharmacoEconomics - Open"},{"key":"1876_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09157-w","volume":"22","author":"M Salas","year":"2022","unstructured":"Salas M, Mordin M, Castro C, Islam Z, Tu N, Hackshaw MD. Health-related quality of life in women with breast cancer: a review of measures. BMC Cancer. 2022;22:66. https:\/\/doi.org\/10.1186\/s12885-021-09157-w.","journal-title":"BMC Cancer"},{"key":"1876_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/BF02966719","volume":"10","author":"T Okamoto","year":"2003","unstructured":"Okamoto T, Shimozuma K, Katsumata N, Koike M, Hisashige A, Tanaka K, et al. Measuring quality of life in patients with breast cancer: a systematic review of reliable and valid instruments available in Japan. Breast Cancer. 2003;10:204\u201313. https:\/\/doi.org\/10.1007\/BF02966719.","journal-title":"Breast Cancer"},{"key":"1876_CR30","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.ejca.2008.05.008","volume":"44","author":"K Cocks","year":"2008","unstructured":"Cocks K, King MT, Velikova G, Fayers PM, Brown JM. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer. 2008;44:1793\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2008.05.008.","journal-title":"Eur J Cancer"},{"key":"1876_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/14740338.2019.1608946","volume":"18","author":"JM Perez-Garcia","year":"2019","unstructured":"Perez-Garcia JM, Cortes J. The safety of eribulin for the treatment of metastatic breast cancer. Expert Opin Drug Saf. 2019;18:347\u201355. https:\/\/doi.org\/10.1080\/14740338.2019.1608946.","journal-title":"Expert Opin Drug Saf"},{"key":"1876_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10549-015-3633-7","volume":"154","author":"J Cortes","year":"2015","unstructured":"Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat. 2015;154:509\u201320. https:\/\/doi.org\/10.1007\/s10549-015-3633-7.","journal-title":"Breast Cancer Res Treat"},{"key":"1876_CR33","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33:594\u2013601. https:\/\/doi.org\/10.1200\/JCO.2013.52.4892.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01876-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:58:36Z","timestamp":1787839116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01876-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1876"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01876-x","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tsuguo Iwatani reports receiving honoraria for lecture (personal) from Eisai, and Eli Lilly. Norikazu Masuda reports receiving grants (institution) from Chugai Pharmaceutical, Eli Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Eisai, Novartis, Gilead Sciences, and Ono Pharmaceutical; receiving honoraria (personal) from Chugai Pharmaceutical, Pfizer, AstraZeneca, Eli Lilly, Daiichi Sankyo, Eisai, Gilead Sciences, and MSD; serving as a representative (unpaid, 2021\u20132025) and a member of the board of directors (unpaid, 2007-current) for Japan Breast Cancer Research Group (JBCRG), a member of the board of directors (unpaid, 2021\u20132024) for Japanese Breast Cancer Society (JBCS), a member of the board of directors (unpaid, 2023\u20132025) for Japan Society of Clinical Oncology (JSCO), a member of the board of directors (unpaid, 2024-current) for Japan Association of Breast Cancer Screening (JABCS), and a representative of the board of directors (unpaid, 2025-current) for Kyoto Breast Cancer Research Network (KBCRN). Shigehira Saji reports receiving grants (institution) from Taiho Pharmaceutical, Eisai, and Takeda Pharmaceutical; grants and contracted clinical trials (institution) from Chugai Pharmaceutical and Daiichi Sankyo; contracted clinical trials (institution) for MSD, AstraZeneca, Gilead Sciences, Eli Lilly and Sanofi; receiving honoraria (personal) from Chugai Pharmaceutical, Kyowa Kirin, MSD, Novartis Pharma, Eisai, Takeda Pharmaceutical, Daiichi Sankyo, Eli Lilly, AstraZeneca, Pfizer, Taiho Pharmaceutical, Ono Pharmaceutical, Nippon Kayaku, Gilead Sciences and Exact Sciences; participation in data safety monitoring board or advisory board (personal) for Chugai\/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo and MSD; serving as an executive board member for JBCRG, JBCS, Japanese Society of Medical Oncology (JSMO), and Breast International Group (BIG). Takuhiro Yamaguchi reports receiving consulting fee (personal) from Eisai. Yasuyuki Kojima reports receiving honoraria (personal) from Daiichi Sankyo, AstraZeneca, Kyowa Kirin, Chugai Pharmaceutical, Eisai, Exact Sciences, MSD, and Taiho Pharmaceutical. Hiroshi Tada reports receiving honoraria (personal) from Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, AstraZeneca, and Pfizer. Kei Koizumi reports receiving honoraria (personal) from Chugai Pharmaceutical, and Pfizer. Hideo Shigematsu reports receiving honoraria (personal) from Daiichi Sankyo, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, MSD, Eisai, Kyowa Kirin, Pfizer, AstraZeneca, Exact Sciences, and Gilead Sciences. Yasuaki Sagara reports receiving honoraria for lecture (personal) from Pfizer, Daiichi Sankyo, Eli Lily, MSD, Kyowa Kirin, AstraZeneca, Eisai, Chugai Pharmaceutical, Nippon Kayaku, and Sysmex. Eriko Tokunaga reports receiving honoraria (personal) from Eli Lilly, Daiichi Sankyo, AstraZeneca, and Chugai Pharmaceutical. Tadahiko Shien reports receiving honoraria (personal) from AstraZeneca, Novartis, MSD, Eisai, Taiho Pharmaceutical, Gilead Sciences, Pfizer, Chugai Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Kyowa Kirin, and Eli Lilly. Uhi Toh reports receiving honoraria (personal) from Chugai Pharmaceutical, Eli Lilly, Pfizer, Daiichi Sankyo, AstraZeneca, and Gilead Sciences. Hiroki Hasegawa and Shun Osaka report full-time employment with Eisai and personal stock ownership in the company. Satoshi Morita reports receiving honoraria (personal) from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly, MSD, and Ono Pharmaceutical. Toshinari Yamashita reports receiving grants (institution) from Chugai Pharmaceutical, Nippon Kayaku, Daiichi Sankyo, Eli Lilly, AstraZeneca, Pfizer, Seagen, MSD, Ono Pharmaceutical, Gilead Sciences and Eisai; receiving honoraria for lecture (personal) from Chugai Pharmaceutical, Eisai, AstraZeneca, Kyowa Kirin, Pfizer, Taiho Pharmaceutical, Eli Lilly, Daiichi Sankyo, MSD, Gilead Sciences, and Exact Sciences. The authors received support from Eisai for medical writing and article processing charges associated with this manuscript. Masahiro Kitada, Tsutomu Iwasa, Toshitaka Okuno, and Yoshie Hasegawa have nothing else to declare related to this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declerations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice (ICH-GCP) guideline, and Ethical Guidelines for Clinical Research of the Ministry of Health, Labour and Welfare of Japan. The protocol was approved by the institutional review board of each participating institution. All patients provided written informed consent prior to screening.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declerations"}}]}}